nodes	percent_of_prediction	percent_of_DWPC	metapath
Lansoprazole—ATP4A—esophageal cancer	0.329	0.631	CbGaD
Lansoprazole—CYP1B1—esophageal cancer	0.149	0.287	CbGaD
Lansoprazole—CYP4A11—Cisplatin—esophageal cancer	0.137	0.528	CbGbCtD
Lansoprazole—ABCB1—esophageal cancer	0.0428	0.0822	CbGaD
Lansoprazole—ABCG2—Carboplatin—esophageal cancer	0.0317	0.122	CbGbCtD
Lansoprazole—ABCG2—Cisplatin—esophageal cancer	0.0271	0.104	CbGbCtD
Lansoprazole—CYP2C9—Capecitabine—esophageal cancer	0.02	0.0769	CbGbCtD
Lansoprazole—ATP4A—gastric juice—esophageal cancer	0.0177	0.41	CbGeAlD
Lansoprazole—ABCG2—Methotrexate—esophageal cancer	0.0176	0.0677	CbGbCtD
Lansoprazole—CYP2C9—Cisplatin—esophageal cancer	0.0101	0.0387	CbGbCtD
Lansoprazole—ABCB1—Cisplatin—esophageal cancer	0.00976	0.0376	CbGbCtD
Lansoprazole—ATP4A—larynx—esophageal cancer	0.00786	0.182	CbGeAlD
Lansoprazole—ABCB1—Methotrexate—esophageal cancer	0.00633	0.0244	CbGbCtD
Lansoprazole—ATP4B—digestive system—esophageal cancer	0.00248	0.0574	CbGeAlD
Lansoprazole—ATP4A—neck—esophageal cancer	0.00208	0.0483	CbGeAlD
Lansoprazole—Esomeprazole—ATP4A—esophageal cancer	0.00144	0.288	CrCbGaD
Lansoprazole—ATP4A—epithelium—esophageal cancer	0.00142	0.0329	CbGeAlD
Lansoprazole—CYP4A11—digestive system—esophageal cancer	0.00134	0.031	CbGeAlD
Lansoprazole—CYP2C18—bronchus—esophageal cancer	0.00115	0.0266	CbGeAlD
Lansoprazole—ATP4A—digestive system—esophageal cancer	0.00108	0.025	CbGeAlD
Lansoprazole—Rabeprazole—ATP4A—esophageal cancer	0.00104	0.208	CrCbGaD
Lansoprazole—Pantoprazole—ATP4A—esophageal cancer	0.00104	0.208	CrCbGaD
Lansoprazole—CYP2C18—digestive system—esophageal cancer	0.000887	0.0205	CbGeAlD
Lansoprazole—Omeprazole—ATP4A—esophageal cancer	0.000849	0.17	CrCbGaD
Lansoprazole—MAPT—lymph node—esophageal cancer	0.00083	0.0192	CbGeAlD
Lansoprazole—CYP1B1—smooth muscle tissue—esophageal cancer	0.000544	0.0126	CbGeAlD
Lansoprazole—CYP1B1—digestive system—esophageal cancer	0.00043	0.00995	CbGeAlD
Lansoprazole—CYP1A1—epithelium—esophageal cancer	0.000399	0.00925	CbGeAlD
Lansoprazole—CYP1A1—bronchus—esophageal cancer	0.000393	0.00911	CbGeAlD
Lansoprazole—Omeprazole—CYP1B1—esophageal cancer	0.000385	0.077	CrCbGaD
Lansoprazole—CYP2C19—digestive system—esophageal cancer	0.000377	0.00873	CbGeAlD
Lansoprazole—CYP1B1—lung—esophageal cancer	0.000359	0.00831	CbGeAlD
Lansoprazole—CYP1A1—trachea—esophageal cancer	0.000353	0.00818	CbGeAlD
Lansoprazole—CYP1A2—digestive system—esophageal cancer	0.000308	0.00713	CbGeAlD
Lansoprazole—CYP1A1—digestive system—esophageal cancer	0.000304	0.00704	CbGeAlD
Lansoprazole—CYP2C9—digestive system—esophageal cancer	0.000292	0.00677	CbGeAlD
Lansoprazole—ABCG2—lung—esophageal cancer	0.000267	0.00619	CbGeAlD
Lansoprazole—CYP1A2—lung—esophageal cancer	0.000257	0.00596	CbGeAlD
Lansoprazole—CYP1A1—lung—esophageal cancer	0.000254	0.00588	CbGeAlD
Lansoprazole—CYP1B1—lymph node—esophageal cancer	0.000245	0.00568	CbGeAlD
Lansoprazole—CYP3A4—digestive system—esophageal cancer	0.000223	0.00516	CbGeAlD
Lansoprazole—CYP2D6—digestive system—esophageal cancer	0.000219	0.00508	CbGeAlD
Lansoprazole—ABCB1—epithelium—esophageal cancer	0.000207	0.0048	CbGeAlD
Lansoprazole—ABCB1—trachea—esophageal cancer	0.000183	0.00425	CbGeAlD
Lansoprazole—ABCG2—lymph node—esophageal cancer	0.000183	0.00423	CbGeAlD
Lansoprazole—CYP1A1—lymph node—esophageal cancer	0.000173	0.00402	CbGeAlD
Lansoprazole—ABCB1—digestive system—esophageal cancer	0.000158	0.00365	CbGeAlD
Lansoprazole—Photosensitivity—Methotrexate—esophageal cancer	0.000136	0.00167	CcSEcCtD
Lansoprazole—Immune system disorder—Cisplatin—esophageal cancer	0.000136	0.00167	CcSEcCtD
Lansoprazole—Mediastinal disorder—Cisplatin—esophageal cancer	0.000136	0.00167	CcSEcCtD
Lansoprazole—Pantoprazole—ABCB1—esophageal cancer	0.000136	0.0271	CrCbGaD
Lansoprazole—Angina pectoris—Capecitabine—esophageal cancer	0.000135	0.00166	CcSEcCtD
Lansoprazole—Arrhythmia—Cisplatin—esophageal cancer	0.000135	0.00165	CcSEcCtD
Lansoprazole—Bronchitis—Capecitabine—esophageal cancer	0.000134	0.00164	CcSEcCtD
Lansoprazole—Alopecia—Cisplatin—esophageal cancer	0.000133	0.00164	CcSEcCtD
Lansoprazole—Abdominal discomfort—Capecitabine—esophageal cancer	0.000133	0.00163	CcSEcCtD
Lansoprazole—Pancytopenia—Capecitabine—esophageal cancer	0.000132	0.00162	CcSEcCtD
Lansoprazole—ABCB1—lung—esophageal cancer	0.000132	0.00305	CbGeAlD
Lansoprazole—Erythema—Cisplatin—esophageal cancer	0.000131	0.00161	CcSEcCtD
Lansoprazole—Malnutrition—Cisplatin—esophageal cancer	0.000131	0.00161	CcSEcCtD
Lansoprazole—Dysuria—Capecitabine—esophageal cancer	0.00013	0.00159	CcSEcCtD
Lansoprazole—Neutropenia—Capecitabine—esophageal cancer	0.00013	0.00159	CcSEcCtD
Lansoprazole—Renal failure acute—Methotrexate—esophageal cancer	0.00013	0.00159	CcSEcCtD
Lansoprazole—Flatulence—Cisplatin—esophageal cancer	0.000129	0.00159	CcSEcCtD
Lansoprazole—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000129	0.00158	CcSEcCtD
Lansoprazole—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000127	0.00156	CcSEcCtD
Lansoprazole—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000127	0.00156	CcSEcCtD
Lansoprazole—Weight increased—Capecitabine—esophageal cancer	0.000126	0.00155	CcSEcCtD
Lansoprazole—Muscle spasms—Cisplatin—esophageal cancer	0.000126	0.00155	CcSEcCtD
Lansoprazole—Hyperglycaemia—Capecitabine—esophageal cancer	0.000125	0.00154	CcSEcCtD
Lansoprazole—Pneumonia—Capecitabine—esophageal cancer	0.000125	0.00153	CcSEcCtD
Lansoprazole—Infestation NOS—Capecitabine—esophageal cancer	0.000124	0.00152	CcSEcCtD
Lansoprazole—Infestation—Capecitabine—esophageal cancer	0.000124	0.00152	CcSEcCtD
Lansoprazole—Vision blurred—Cisplatin—esophageal cancer	0.000124	0.00152	CcSEcCtD
Lansoprazole—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000124	0.00152	CcSEcCtD
Lansoprazole—Tremor—Cisplatin—esophageal cancer	0.000123	0.00151	CcSEcCtD
Lansoprazole—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000123	0.00151	CcSEcCtD
Lansoprazole—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000122	0.0015	CcSEcCtD
Lansoprazole—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000122	0.0015	CcSEcCtD
Lansoprazole—Ill-defined disorder—Cisplatin—esophageal cancer	0.000122	0.0015	CcSEcCtD
Lansoprazole—Renal failure—Capecitabine—esophageal cancer	0.000122	0.00149	CcSEcCtD
Lansoprazole—Myocardial infarction—Capecitabine—esophageal cancer	0.000121	0.00149	CcSEcCtD
Lansoprazole—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000121	0.00149	CcSEcCtD
Lansoprazole—Anaemia—Cisplatin—esophageal cancer	0.000121	0.00149	CcSEcCtD
Lansoprazole—Stomatitis—Capecitabine—esophageal cancer	0.000121	0.00148	CcSEcCtD
Lansoprazole—Jaundice—Capecitabine—esophageal cancer	0.000121	0.00148	CcSEcCtD
Lansoprazole—Urinary tract infection—Capecitabine—esophageal cancer	0.00012	0.00148	CcSEcCtD
Lansoprazole—Conjunctivitis—Capecitabine—esophageal cancer	0.00012	0.00148	CcSEcCtD
Lansoprazole—Osteoarthritis—Methotrexate—esophageal cancer	0.00012	0.00147	CcSEcCtD
Lansoprazole—Malaise—Cisplatin—esophageal cancer	0.000118	0.00145	CcSEcCtD
Lansoprazole—Haematuria—Capecitabine—esophageal cancer	0.000118	0.00145	CcSEcCtD
Lansoprazole—Leukopenia—Cisplatin—esophageal cancer	0.000118	0.00144	CcSEcCtD
Lansoprazole—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000117	0.00144	CcSEcCtD
Lansoprazole—Epistaxis—Capecitabine—esophageal cancer	0.000117	0.00143	CcSEcCtD
Lansoprazole—Agranulocytosis—Capecitabine—esophageal cancer	0.000116	0.00142	CcSEcCtD
Lansoprazole—Convulsion—Cisplatin—esophageal cancer	0.000114	0.0014	CcSEcCtD
Lansoprazole—Mood swings—Methotrexate—esophageal cancer	0.000113	0.00139	CcSEcCtD
Lansoprazole—Bradycardia—Capecitabine—esophageal cancer	0.000113	0.00139	CcSEcCtD
Lansoprazole—Myalgia—Cisplatin—esophageal cancer	0.000112	0.00137	CcSEcCtD
Lansoprazole—Rhinitis—Capecitabine—esophageal cancer	0.000111	0.00137	CcSEcCtD
Lansoprazole—Anxiety—Cisplatin—esophageal cancer	0.000111	0.00137	CcSEcCtD
Lansoprazole—Hepatitis—Capecitabine—esophageal cancer	0.000111	0.00136	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000111	0.00136	CcSEcCtD
Lansoprazole—Hypoaesthesia—Capecitabine—esophageal cancer	0.000111	0.00136	CcSEcCtD
Lansoprazole—Omeprazole—ABCB1—esophageal cancer	0.000111	0.0221	CrCbGaD
Lansoprazole—Liver function test abnormal—Methotrexate—esophageal cancer	0.00011	0.00136	CcSEcCtD
Lansoprazole—Discomfort—Cisplatin—esophageal cancer	0.00011	0.00136	CcSEcCtD
Lansoprazole—Pharyngitis—Capecitabine—esophageal cancer	0.00011	0.00135	CcSEcCtD
Lansoprazole—Urinary tract disorder—Capecitabine—esophageal cancer	0.00011	0.00135	CcSEcCtD
Lansoprazole—Oedema peripheral—Capecitabine—esophageal cancer	0.00011	0.00134	CcSEcCtD
Lansoprazole—Connective tissue disorder—Capecitabine—esophageal cancer	0.000109	0.00134	CcSEcCtD
Lansoprazole—Urethral disorder—Capecitabine—esophageal cancer	0.000109	0.00134	CcSEcCtD
Lansoprazole—Breast disorder—Methotrexate—esophageal cancer	0.000108	0.00133	CcSEcCtD
Lansoprazole—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000108	0.00132	CcSEcCtD
Lansoprazole—Anaphylactic shock—Cisplatin—esophageal cancer	0.000107	0.00132	CcSEcCtD
Lansoprazole—Oedema—Cisplatin—esophageal cancer	0.000107	0.00132	CcSEcCtD
Lansoprazole—Visual impairment—Capecitabine—esophageal cancer	0.000107	0.00132	CcSEcCtD
Lansoprazole—Infection—Cisplatin—esophageal cancer	0.000106	0.00131	CcSEcCtD
Lansoprazole—Erythema multiforme—Capecitabine—esophageal cancer	0.000105	0.00129	CcSEcCtD
Lansoprazole—Nervous system disorder—Cisplatin—esophageal cancer	0.000105	0.00129	CcSEcCtD
Lansoprazole—Thrombocytopenia—Cisplatin—esophageal cancer	0.000105	0.00129	CcSEcCtD
Lansoprazole—Tachycardia—Cisplatin—esophageal cancer	0.000105	0.00128	CcSEcCtD
Lansoprazole—Skin disorder—Cisplatin—esophageal cancer	0.000104	0.00128	CcSEcCtD
Lansoprazole—Eye disorder—Capecitabine—esophageal cancer	0.000104	0.00128	CcSEcCtD
Lansoprazole—Tinnitus—Capecitabine—esophageal cancer	0.000104	0.00127	CcSEcCtD
Lansoprazole—Hyperhidrosis—Cisplatin—esophageal cancer	0.000104	0.00127	CcSEcCtD
Lansoprazole—Asthma—Methotrexate—esophageal cancer	0.000103	0.00127	CcSEcCtD
Lansoprazole—Cardiac disorder—Capecitabine—esophageal cancer	0.000103	0.00127	CcSEcCtD
Lansoprazole—Eosinophilia—Methotrexate—esophageal cancer	0.000102	0.00126	CcSEcCtD
Lansoprazole—Anorexia—Cisplatin—esophageal cancer	0.000102	0.00125	CcSEcCtD
Lansoprazole—Pancreatitis—Methotrexate—esophageal cancer	0.000101	0.00124	CcSEcCtD
Lansoprazole—Angiopathy—Capecitabine—esophageal cancer	0.000101	0.00124	CcSEcCtD
Lansoprazole—Immune system disorder—Capecitabine—esophageal cancer	0.0001	0.00123	CcSEcCtD
Lansoprazole—Mediastinal disorder—Capecitabine—esophageal cancer	0.0001	0.00123	CcSEcCtD
Lansoprazole—Hypotension—Cisplatin—esophageal cancer	0.0001	0.00123	CcSEcCtD
Lansoprazole—Chills—Capecitabine—esophageal cancer	9.98e-05	0.00122	CcSEcCtD
Lansoprazole—Arrhythmia—Capecitabine—esophageal cancer	9.93e-05	0.00122	CcSEcCtD
Lansoprazole—Abdominal discomfort—Methotrexate—esophageal cancer	9.91e-05	0.00122	CcSEcCtD
Lansoprazole—Alopecia—Capecitabine—esophageal cancer	9.82e-05	0.00121	CcSEcCtD
Lansoprazole—Pancytopenia—Methotrexate—esophageal cancer	9.82e-05	0.00121	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Cisplatin—esophageal cancer	9.76e-05	0.0012	CcSEcCtD
Lansoprazole—Mental disorder—Capecitabine—esophageal cancer	9.74e-05	0.0012	CcSEcCtD
Lansoprazole—Malnutrition—Capecitabine—esophageal cancer	9.68e-05	0.00119	CcSEcCtD
Lansoprazole—Erythema—Capecitabine—esophageal cancer	9.68e-05	0.00119	CcSEcCtD
Lansoprazole—Dysuria—Methotrexate—esophageal cancer	9.67e-05	0.00119	CcSEcCtD
Lansoprazole—Neutropenia—Methotrexate—esophageal cancer	9.67e-05	0.00119	CcSEcCtD
Lansoprazole—Paraesthesia—Cisplatin—esophageal cancer	9.62e-05	0.00118	CcSEcCtD
Lansoprazole—Upper respiratory tract infection—Methotrexate—esophageal cancer	9.61e-05	0.00118	CcSEcCtD
Lansoprazole—Dyspnoea—Cisplatin—esophageal cancer	9.55e-05	0.00117	CcSEcCtD
Lansoprazole—Flatulence—Capecitabine—esophageal cancer	9.54e-05	0.00117	CcSEcCtD
Lansoprazole—Erectile dysfunction—Methotrexate—esophageal cancer	9.52e-05	0.00117	CcSEcCtD
Lansoprazole—Dysgeusia—Capecitabine—esophageal cancer	9.48e-05	0.00116	CcSEcCtD
Lansoprazole—Photosensitivity reaction—Methotrexate—esophageal cancer	9.44e-05	0.00116	CcSEcCtD
Lansoprazole—Back pain—Capecitabine—esophageal cancer	9.36e-05	0.00115	CcSEcCtD
Lansoprazole—Decreased appetite—Cisplatin—esophageal cancer	9.32e-05	0.00114	CcSEcCtD
Lansoprazole—Muscle spasms—Capecitabine—esophageal cancer	9.31e-05	0.00114	CcSEcCtD
Lansoprazole—Pneumonia—Methotrexate—esophageal cancer	9.27e-05	0.00114	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Cisplatin—esophageal cancer	9.25e-05	0.00114	CcSEcCtD
Lansoprazole—Infestation NOS—Methotrexate—esophageal cancer	9.22e-05	0.00113	CcSEcCtD
Lansoprazole—Infestation—Methotrexate—esophageal cancer	9.22e-05	0.00113	CcSEcCtD
Lansoprazole—Pain—Cisplatin—esophageal cancer	9.16e-05	0.00112	CcSEcCtD
Lansoprazole—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	9.14e-05	0.00112	CcSEcCtD
Lansoprazole—Vision blurred—Capecitabine—esophageal cancer	9.12e-05	0.00112	CcSEcCtD
Lansoprazole—Tremor—Capecitabine—esophageal cancer	9.07e-05	0.00111	CcSEcCtD
Lansoprazole—Renal failure—Methotrexate—esophageal cancer	9.06e-05	0.00111	CcSEcCtD
Lansoprazole—ABCB1—lymph node—esophageal cancer	9.01e-05	0.00209	CbGeAlD
Lansoprazole—Stomatitis—Methotrexate—esophageal cancer	8.99e-05	0.0011	CcSEcCtD
Lansoprazole—Ill-defined disorder—Capecitabine—esophageal cancer	8.98e-05	0.0011	CcSEcCtD
Lansoprazole—Conjunctivitis—Methotrexate—esophageal cancer	8.96e-05	0.0011	CcSEcCtD
Lansoprazole—Anaemia—Capecitabine—esophageal cancer	8.95e-05	0.0011	CcSEcCtD
Lansoprazole—Sweating—Methotrexate—esophageal cancer	8.84e-05	0.00108	CcSEcCtD
Lansoprazole—Feeling abnormal—Cisplatin—esophageal cancer	8.83e-05	0.00108	CcSEcCtD
Lansoprazole—Haematuria—Methotrexate—esophageal cancer	8.79e-05	0.00108	CcSEcCtD
Lansoprazole—Malaise—Capecitabine—esophageal cancer	8.73e-05	0.00107	CcSEcCtD
Lansoprazole—Hepatobiliary disease—Methotrexate—esophageal cancer	8.72e-05	0.00107	CcSEcCtD
Lansoprazole—Epistaxis—Methotrexate—esophageal cancer	8.7e-05	0.00107	CcSEcCtD
Lansoprazole—Vertigo—Capecitabine—esophageal cancer	8.7e-05	0.00107	CcSEcCtD
Lansoprazole—Syncope—Capecitabine—esophageal cancer	8.68e-05	0.00107	CcSEcCtD
Lansoprazole—Leukopenia—Capecitabine—esophageal cancer	8.66e-05	0.00106	CcSEcCtD
Lansoprazole—Agranulocytosis—Methotrexate—esophageal cancer	8.6e-05	0.00106	CcSEcCtD
Lansoprazole—Palpitations—Capecitabine—esophageal cancer	8.55e-05	0.00105	CcSEcCtD
Lansoprazole—Loss of consciousness—Capecitabine—esophageal cancer	8.51e-05	0.00104	CcSEcCtD
Lansoprazole—Body temperature increased—Cisplatin—esophageal cancer	8.47e-05	0.00104	CcSEcCtD
Lansoprazole—Cough—Capecitabine—esophageal cancer	8.45e-05	0.00104	CcSEcCtD
Lansoprazole—Hypertension—Capecitabine—esophageal cancer	8.36e-05	0.00103	CcSEcCtD
Lansoprazole—Hepatitis—Methotrexate—esophageal cancer	8.28e-05	0.00102	CcSEcCtD
Lansoprazole—Arthralgia—Capecitabine—esophageal cancer	8.24e-05	0.00101	CcSEcCtD
Lansoprazole—Chest pain—Capecitabine—esophageal cancer	8.24e-05	0.00101	CcSEcCtD
Lansoprazole—Myalgia—Capecitabine—esophageal cancer	8.24e-05	0.00101	CcSEcCtD
Lansoprazole—Pharyngitis—Methotrexate—esophageal cancer	8.21e-05	0.00101	CcSEcCtD
Lansoprazole—Anxiety—Capecitabine—esophageal cancer	8.21e-05	0.00101	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	8.18e-05	0.001	CcSEcCtD
Lansoprazole—Urinary tract disorder—Methotrexate—esophageal cancer	8.17e-05	0.001	CcSEcCtD
Lansoprazole—Discomfort—Capecitabine—esophageal cancer	8.14e-05	0.000999	CcSEcCtD
Lansoprazole—Urethral disorder—Methotrexate—esophageal cancer	8.11e-05	0.000996	CcSEcCtD
Lansoprazole—Dry mouth—Capecitabine—esophageal cancer	8.06e-05	0.000989	CcSEcCtD
Lansoprazole—Visual impairment—Methotrexate—esophageal cancer	7.98e-05	0.000979	CcSEcCtD
Lansoprazole—Confusional state—Capecitabine—esophageal cancer	7.96e-05	0.000978	CcSEcCtD
Lansoprazole—Oedema—Capecitabine—esophageal cancer	7.9e-05	0.00097	CcSEcCtD
Lansoprazole—Hypersensitivity—Cisplatin—esophageal cancer	7.9e-05	0.000969	CcSEcCtD
Lansoprazole—Infection—Capecitabine—esophageal cancer	7.85e-05	0.000963	CcSEcCtD
Lansoprazole—Erythema multiforme—Methotrexate—esophageal cancer	7.83e-05	0.000961	CcSEcCtD
Lansoprazole—Shock—Capecitabine—esophageal cancer	7.77e-05	0.000954	CcSEcCtD
Lansoprazole—Nervous system disorder—Capecitabine—esophageal cancer	7.75e-05	0.000951	CcSEcCtD
Lansoprazole—Eye disorder—Methotrexate—esophageal cancer	7.73e-05	0.000949	CcSEcCtD
Lansoprazole—Thrombocytopenia—Capecitabine—esophageal cancer	7.73e-05	0.000949	CcSEcCtD
Lansoprazole—Tinnitus—Methotrexate—esophageal cancer	7.72e-05	0.000947	CcSEcCtD
Lansoprazole—Tachycardia—Capecitabine—esophageal cancer	7.71e-05	0.000946	CcSEcCtD
Lansoprazole—Asthenia—Cisplatin—esophageal cancer	7.69e-05	0.000944	CcSEcCtD
Lansoprazole—Cardiac disorder—Methotrexate—esophageal cancer	7.68e-05	0.000943	CcSEcCtD
Lansoprazole—Skin disorder—Capecitabine—esophageal cancer	7.67e-05	0.000942	CcSEcCtD
Lansoprazole—Hyperhidrosis—Capecitabine—esophageal cancer	7.64e-05	0.000937	CcSEcCtD
Lansoprazole—Anorexia—Capecitabine—esophageal cancer	7.53e-05	0.000924	CcSEcCtD
Lansoprazole—Angiopathy—Methotrexate—esophageal cancer	7.51e-05	0.000922	CcSEcCtD
Lansoprazole—Immune system disorder—Methotrexate—esophageal cancer	7.48e-05	0.000918	CcSEcCtD
Lansoprazole—Mediastinal disorder—Methotrexate—esophageal cancer	7.46e-05	0.000916	CcSEcCtD
Lansoprazole—Chills—Methotrexate—esophageal cancer	7.43e-05	0.000912	CcSEcCtD
Lansoprazole—Hypotension—Capecitabine—esophageal cancer	7.38e-05	0.000906	CcSEcCtD
Lansoprazole—Diarrhoea—Cisplatin—esophageal cancer	7.33e-05	0.0009	CcSEcCtD
Lansoprazole—Alopecia—Methotrexate—esophageal cancer	7.31e-05	0.000898	CcSEcCtD
Lansoprazole—Mental disorder—Methotrexate—esophageal cancer	7.25e-05	0.00089	CcSEcCtD
Lansoprazole—Erythema—Methotrexate—esophageal cancer	7.21e-05	0.000884	CcSEcCtD
Lansoprazole—Malnutrition—Methotrexate—esophageal cancer	7.21e-05	0.000884	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Capecitabine—esophageal cancer	7.2e-05	0.000883	CcSEcCtD
Lansoprazole—Insomnia—Capecitabine—esophageal cancer	7.14e-05	0.000877	CcSEcCtD
Lansoprazole—Paraesthesia—Capecitabine—esophageal cancer	7.09e-05	0.000871	CcSEcCtD
Lansoprazole—Dysgeusia—Methotrexate—esophageal cancer	7.06e-05	0.000866	CcSEcCtD
Lansoprazole—Dyspnoea—Capecitabine—esophageal cancer	7.04e-05	0.000864	CcSEcCtD
Lansoprazole—Back pain—Methotrexate—esophageal cancer	6.97e-05	0.000855	CcSEcCtD
Lansoprazole—Dyspepsia—Capecitabine—esophageal cancer	6.95e-05	0.000853	CcSEcCtD
Lansoprazole—Decreased appetite—Capecitabine—esophageal cancer	6.87e-05	0.000843	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Capecitabine—esophageal cancer	6.82e-05	0.000837	CcSEcCtD
Lansoprazole—Vomiting—Cisplatin—esophageal cancer	6.81e-05	0.000836	CcSEcCtD
Lansoprazole—Fatigue—Capecitabine—esophageal cancer	6.81e-05	0.000836	CcSEcCtD
Lansoprazole—Vision blurred—Methotrexate—esophageal cancer	6.79e-05	0.000833	CcSEcCtD
Lansoprazole—Rash—Cisplatin—esophageal cancer	6.76e-05	0.000829	CcSEcCtD
Lansoprazole—Pain—Capecitabine—esophageal cancer	6.75e-05	0.000829	CcSEcCtD
Lansoprazole—Constipation—Capecitabine—esophageal cancer	6.75e-05	0.000829	CcSEcCtD
Lansoprazole—Dermatitis—Cisplatin—esophageal cancer	6.75e-05	0.000829	CcSEcCtD
Lansoprazole—Ill-defined disorder—Methotrexate—esophageal cancer	6.69e-05	0.000821	CcSEcCtD
Lansoprazole—Anaemia—Methotrexate—esophageal cancer	6.66e-05	0.000817	CcSEcCtD
Lansoprazole—Feeling abnormal—Capecitabine—esophageal cancer	6.51e-05	0.000799	CcSEcCtD
Lansoprazole—Malaise—Methotrexate—esophageal cancer	6.5e-05	0.000798	CcSEcCtD
Lansoprazole—Vertigo—Methotrexate—esophageal cancer	6.47e-05	0.000795	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Capecitabine—esophageal cancer	6.46e-05	0.000793	CcSEcCtD
Lansoprazole—Leukopenia—Methotrexate—esophageal cancer	6.45e-05	0.000792	CcSEcCtD
Lansoprazole—Nausea—Cisplatin—esophageal cancer	6.37e-05	0.000781	CcSEcCtD
Lansoprazole—Cough—Methotrexate—esophageal cancer	6.29e-05	0.000772	CcSEcCtD
Lansoprazole—Urticaria—Capecitabine—esophageal cancer	6.28e-05	0.00077	CcSEcCtD
Lansoprazole—Abdominal pain—Capecitabine—esophageal cancer	6.24e-05	0.000766	CcSEcCtD
Lansoprazole—Body temperature increased—Capecitabine—esophageal cancer	6.24e-05	0.000766	CcSEcCtD
Lansoprazole—Convulsion—Methotrexate—esophageal cancer	6.24e-05	0.000766	CcSEcCtD
Lansoprazole—Arthralgia—Methotrexate—esophageal cancer	6.13e-05	0.000753	CcSEcCtD
Lansoprazole—Chest pain—Methotrexate—esophageal cancer	6.13e-05	0.000753	CcSEcCtD
Lansoprazole—Myalgia—Methotrexate—esophageal cancer	6.13e-05	0.000753	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	6.09e-05	0.000748	CcSEcCtD
Lansoprazole—Discomfort—Methotrexate—esophageal cancer	6.06e-05	0.000744	CcSEcCtD
Lansoprazole—Confusional state—Methotrexate—esophageal cancer	5.93e-05	0.000728	CcSEcCtD
Lansoprazole—Anaphylactic shock—Methotrexate—esophageal cancer	5.88e-05	0.000722	CcSEcCtD
Lansoprazole—Infection—Methotrexate—esophageal cancer	5.84e-05	0.000717	CcSEcCtD
Lansoprazole—Hypersensitivity—Capecitabine—esophageal cancer	5.82e-05	0.000714	CcSEcCtD
Lansoprazole—Nervous system disorder—Methotrexate—esophageal cancer	5.77e-05	0.000708	CcSEcCtD
Lansoprazole—Thrombocytopenia—Methotrexate—esophageal cancer	5.76e-05	0.000707	CcSEcCtD
Lansoprazole—Skin disorder—Methotrexate—esophageal cancer	5.71e-05	0.000701	CcSEcCtD
Lansoprazole—Hyperhidrosis—Methotrexate—esophageal cancer	5.68e-05	0.000698	CcSEcCtD
Lansoprazole—Asthenia—Capecitabine—esophageal cancer	5.67e-05	0.000696	CcSEcCtD
Lansoprazole—Anorexia—Methotrexate—esophageal cancer	5.61e-05	0.000688	CcSEcCtD
Lansoprazole—Pruritus—Capecitabine—esophageal cancer	5.59e-05	0.000686	CcSEcCtD
Lansoprazole—Hypotension—Methotrexate—esophageal cancer	5.49e-05	0.000674	CcSEcCtD
Lansoprazole—Diarrhoea—Capecitabine—esophageal cancer	5.4e-05	0.000663	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Methotrexate—esophageal cancer	5.36e-05	0.000658	CcSEcCtD
Lansoprazole—Insomnia—Methotrexate—esophageal cancer	5.32e-05	0.000653	CcSEcCtD
Lansoprazole—Paraesthesia—Methotrexate—esophageal cancer	5.28e-05	0.000648	CcSEcCtD
Lansoprazole—Dyspnoea—Methotrexate—esophageal cancer	5.24e-05	0.000644	CcSEcCtD
Lansoprazole—Somnolence—Methotrexate—esophageal cancer	5.23e-05	0.000642	CcSEcCtD
Lansoprazole—Dizziness—Capecitabine—esophageal cancer	5.22e-05	0.000641	CcSEcCtD
Lansoprazole—Dyspepsia—Methotrexate—esophageal cancer	5.18e-05	0.000635	CcSEcCtD
Lansoprazole—Decreased appetite—Methotrexate—esophageal cancer	5.11e-05	0.000627	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Methotrexate—esophageal cancer	5.08e-05	0.000623	CcSEcCtD
Lansoprazole—Fatigue—Methotrexate—esophageal cancer	5.07e-05	0.000622	CcSEcCtD
Lansoprazole—Pain—Methotrexate—esophageal cancer	5.03e-05	0.000617	CcSEcCtD
Lansoprazole—Vomiting—Capecitabine—esophageal cancer	5.02e-05	0.000616	CcSEcCtD
Lansoprazole—Rash—Capecitabine—esophageal cancer	4.98e-05	0.000611	CcSEcCtD
Lansoprazole—Dermatitis—Capecitabine—esophageal cancer	4.98e-05	0.000611	CcSEcCtD
Lansoprazole—Headache—Capecitabine—esophageal cancer	4.95e-05	0.000607	CcSEcCtD
Lansoprazole—Feeling abnormal—Methotrexate—esophageal cancer	4.85e-05	0.000595	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Methotrexate—esophageal cancer	4.81e-05	0.00059	CcSEcCtD
Lansoprazole—Nausea—Capecitabine—esophageal cancer	4.69e-05	0.000576	CcSEcCtD
Lansoprazole—Urticaria—Methotrexate—esophageal cancer	4.67e-05	0.000573	CcSEcCtD
Lansoprazole—Body temperature increased—Methotrexate—esophageal cancer	4.65e-05	0.000571	CcSEcCtD
Lansoprazole—Abdominal pain—Methotrexate—esophageal cancer	4.65e-05	0.000571	CcSEcCtD
Lansoprazole—Hypersensitivity—Methotrexate—esophageal cancer	4.33e-05	0.000532	CcSEcCtD
Lansoprazole—Asthenia—Methotrexate—esophageal cancer	4.22e-05	0.000518	CcSEcCtD
Lansoprazole—Pruritus—Methotrexate—esophageal cancer	4.16e-05	0.000511	CcSEcCtD
Lansoprazole—Diarrhoea—Methotrexate—esophageal cancer	4.02e-05	0.000494	CcSEcCtD
Lansoprazole—Dizziness—Methotrexate—esophageal cancer	3.89e-05	0.000477	CcSEcCtD
Lansoprazole—Vomiting—Methotrexate—esophageal cancer	3.74e-05	0.000459	CcSEcCtD
Lansoprazole—Rash—Methotrexate—esophageal cancer	3.71e-05	0.000455	CcSEcCtD
Lansoprazole—Dermatitis—Methotrexate—esophageal cancer	3.7e-05	0.000455	CcSEcCtD
Lansoprazole—Headache—Methotrexate—esophageal cancer	3.68e-05	0.000452	CcSEcCtD
Lansoprazole—Nausea—Methotrexate—esophageal cancer	3.49e-05	0.000429	CcSEcCtD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	7.08e-06	7.88e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—TYMP—esophageal cancer	7.07e-06	7.87e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CYP26A1—esophageal cancer	7.04e-06	7.84e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—ALDOB—esophageal cancer	7.03e-06	7.83e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ADH1B—esophageal cancer	6.97e-06	7.76e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—GNG7—esophageal cancer	6.96e-06	7.75e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	6.94e-06	7.72e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ADH1B—esophageal cancer	6.91e-06	7.69e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—HMOX1—esophageal cancer	6.89e-06	7.67e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CYP26A1—esophageal cancer	6.87e-06	7.66e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—CYP19A1—esophageal cancer	6.87e-06	7.65e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—ALOX15—esophageal cancer	6.86e-06	7.64e-05	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—CREBBP—esophageal cancer	6.86e-06	7.64e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	6.78e-06	7.55e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—GAPDH—esophageal cancer	6.77e-06	7.54e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	6.76e-06	7.52e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PLCE1—esophageal cancer	6.73e-06	7.5e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ADH7—esophageal cancer	6.73e-06	7.5e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CRABP1—esophageal cancer	6.71e-06	7.47e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—ALOX15—esophageal cancer	6.7e-06	7.46e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—TYMP—esophageal cancer	6.66e-06	7.42e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	6.65e-06	7.41e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—ABCB1—esophageal cancer	6.61e-06	7.36e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—TYMP—esophageal cancer	6.6e-06	7.35e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—TPI1—esophageal cancer	6.55e-06	7.29e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—GSTO1—esophageal cancer	6.55e-06	7.29e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—ALDH2—esophageal cancer	6.52e-06	7.26e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CYP26A1—esophageal cancer	6.48e-06	7.21e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CYP26A1—esophageal cancer	6.42e-06	7.15e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—TPI1—esophageal cancer	6.39e-06	7.12e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—GSTO1—esophageal cancer	6.39e-06	7.12e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—GNG7—esophageal cancer	6.38e-06	7.11e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ALOX15—esophageal cancer	6.31e-06	7.03e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—ALDOB—esophageal cancer	6.28e-06	6.99e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—HMOX1—esophageal cancer	6.27e-06	6.98e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ALOX15—esophageal cancer	6.26e-06	6.97e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—GSTT1—esophageal cancer	6.2e-06	6.91e-05	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—NOS3—esophageal cancer	6.14e-06	6.84e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—CYP2A6—esophageal cancer	6.13e-06	6.83e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—ALDOB—esophageal cancer	6.13e-06	6.82e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—SLC10A2—esophageal cancer	6.11e-06	6.81e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CA1—esophageal cancer	6.11e-06	6.81e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	6.11e-06	6.8e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—GAPDH—esophageal cancer	6.04e-06	6.73e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—GSTO1—esophageal cancer	6.02e-06	6.71e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—TPI1—esophageal cancer	6.02e-06	6.71e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—ABCB1—esophageal cancer	6.01e-06	6.7e-05	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—CREBBP—esophageal cancer	5.99e-06	6.67e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CRABP1—esophageal cancer	5.99e-06	6.67e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—ALDH2—esophageal cancer	5.98e-06	6.66e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—GSTO1—esophageal cancer	5.97e-06	6.65e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—TPI1—esophageal cancer	5.97e-06	6.65e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ADH1B—esophageal cancer	5.9e-06	6.57e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—GAPDH—esophageal cancer	5.9e-06	6.57e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	5.89e-06	6.56e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CRABP1—esophageal cancer	5.85e-06	6.51e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—ENO1—esophageal cancer	5.81e-06	6.48e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PTGS1—esophageal cancer	5.81e-06	6.48e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ALDOB—esophageal cancer	5.77e-06	6.43e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PSME2—esophageal cancer	5.73e-06	6.38e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PSME1—esophageal cancer	5.73e-06	6.38e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ALDOB—esophageal cancer	5.72e-06	6.38e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—GNG7—esophageal cancer	5.7e-06	6.34e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	5.7e-06	6.34e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—GSTT1—esophageal cancer	5.69e-06	6.34e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—TYMP—esophageal cancer	5.64e-06	6.28e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CYP2A6—esophageal cancer	5.62e-06	6.26e-05	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PTGS2—esophageal cancer	5.61e-06	6.25e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	5.6e-06	6.24e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CA2—esophageal cancer	5.59e-06	6.22e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—GNG7—esophageal cancer	5.56e-06	6.19e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—GAPDH—esophageal cancer	5.56e-06	6.19e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—GAPDH—esophageal cancer	5.51e-06	6.14e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CRABP1—esophageal cancer	5.51e-06	6.13e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CYP26A1—esophageal cancer	5.49e-06	6.11e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CRABP1—esophageal cancer	5.46e-06	6.08e-05	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—NOS3—esophageal cancer	5.37e-06	5.98e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ALOX15—esophageal cancer	5.35e-06	5.96e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—ALDH2—esophageal cancer	5.34e-06	5.94e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—ENO1—esophageal cancer	5.33e-06	5.94e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PTGS1—esophageal cancer	5.33e-06	5.94e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PSME1—esophageal cancer	5.25e-06	5.85e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PSME2—esophageal cancer	5.25e-06	5.85e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—GNG7—esophageal cancer	5.24e-06	5.84e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—ALDH2—esophageal cancer	5.21e-06	5.8e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PLCE1—esophageal cancer	5.2e-06	5.79e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ADH7—esophageal cancer	5.2e-06	5.79e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—GNG7—esophageal cancer	5.19e-06	5.78e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GSTO1—esophageal cancer	5.1e-06	5.68e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—TPI1—esophageal cancer	5.1e-06	5.68e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—GSTT1—esophageal cancer	5.08e-06	5.65e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CYP2A6—esophageal cancer	5.02e-06	5.59e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	5e-06	5.57e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	5e-06	5.57e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	5e-06	5.57e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—GSTT1—esophageal cancer	4.96e-06	5.52e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—CYP1B1—esophageal cancer	4.94e-06	5.51e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ALDH2—esophageal cancer	4.91e-06	5.47e-05	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PTGS2—esophageal cancer	4.91e-06	5.47e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CYP2A6—esophageal cancer	4.9e-06	5.46e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ALDOB—esophageal cancer	4.89e-06	5.45e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ALDH2—esophageal cancer	4.87e-06	5.42e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—ENO1—esophageal cancer	4.76e-06	5.3e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PTGS1—esophageal cancer	4.76e-06	5.3e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GAPDH—esophageal cancer	4.71e-06	5.24e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PSME1—esophageal cancer	4.69e-06	5.22e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PSME2—esophageal cancer	4.69e-06	5.22e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—GSTT1—esophageal cancer	4.67e-06	5.2e-05	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—EP300—esophageal cancer	4.67e-06	5.2e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CRABP1—esophageal cancer	4.67e-06	5.2e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—CYP19A1—esophageal cancer	4.65e-06	5.18e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PTGS1—esophageal cancer	4.64e-06	5.17e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—ENO1—esophageal cancer	4.64e-06	5.17e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	4.64e-06	5.17e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—GSTT1—esophageal cancer	4.63e-06	5.16e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CYP2A6—esophageal cancer	4.62e-06	5.14e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	4.59e-06	5.11e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CYP2A6—esophageal cancer	4.58e-06	5.1e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PSME2—esophageal cancer	4.58e-06	5.1e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PSME1—esophageal cancer	4.58e-06	5.1e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	4.56e-06	5.08e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ADH1B—esophageal cancer	4.56e-06	5.07e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CYP1B1—esophageal cancer	4.53e-06	5.05e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GNG7—esophageal cancer	4.44e-06	4.94e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—CREBBP—esophageal cancer	4.42e-06	4.92e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ENO1—esophageal cancer	4.38e-06	4.87e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PTGS1—esophageal cancer	4.38e-06	4.87e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—TYMP—esophageal cancer	4.35e-06	4.85e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PTGS1—esophageal cancer	4.34e-06	4.83e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ENO1—esophageal cancer	4.34e-06	4.83e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PSME1—esophageal cancer	4.31e-06	4.8e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PSME2—esophageal cancer	4.31e-06	4.8e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PSME2—esophageal cancer	4.27e-06	4.76e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PSME1—esophageal cancer	4.27e-06	4.76e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CYP19A1—esophageal cancer	4.26e-06	4.75e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—HMOX1—esophageal cancer	4.24e-06	4.72e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CYP26A1—esophageal cancer	4.24e-06	4.72e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	4.16e-06	4.63e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ALDH2—esophageal cancer	4.16e-06	4.63e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ALOX15—esophageal cancer	4.13e-06	4.6e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	4.09e-06	4.56e-05	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—EP300—esophageal cancer	4.08e-06	4.55e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—ABCB1—esophageal cancer	4.07e-06	4.53e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CYP1B1—esophageal cancer	4.05e-06	4.51e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—CREBBP—esophageal cancer	4.02e-06	4.48e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GSTT1—esophageal cancer	3.96e-06	4.41e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—NOS3—esophageal cancer	3.96e-06	4.41e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CYP1B1—esophageal cancer	3.95e-06	4.4e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—TPI1—esophageal cancer	3.94e-06	4.39e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GSTO1—esophageal cancer	3.94e-06	4.39e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CYP2A6—esophageal cancer	3.91e-06	4.36e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	3.9e-06	4.34e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—HMOX1—esophageal cancer	3.89e-06	4.33e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.81e-06	4.25e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CYP19A1—esophageal cancer	3.8e-06	4.24e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ALDOB—esophageal cancer	3.78e-06	4.2e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	3.73e-06	4.16e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—ABCB1—esophageal cancer	3.73e-06	4.16e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CYP1B1—esophageal cancer	3.72e-06	4.14e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CYP19A1—esophageal cancer	3.71e-06	4.13e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ENO1—esophageal cancer	3.71e-06	4.13e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PTGS1—esophageal cancer	3.71e-06	4.13e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CYP1B1—esophageal cancer	3.69e-06	4.11e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PSME1—esophageal cancer	3.65e-06	4.07e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PSME2—esophageal cancer	3.65e-06	4.07e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GAPDH—esophageal cancer	3.63e-06	4.05e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PTGS2—esophageal cancer	3.62e-06	4.03e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CRABP1—esophageal cancer	3.6e-06	4.01e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—NOS3—esophageal cancer	3.6e-06	4.01e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CYP19A1—esophageal cancer	3.5e-06	3.9e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—HMOX1—esophageal cancer	3.47e-06	3.87e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CYP19A1—esophageal cancer	3.47e-06	3.86e-05	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PIK3CA—esophageal cancer	3.45e-06	3.85e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GNG7—esophageal cancer	3.43e-06	3.82e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.4e-06	3.79e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—HMOX1—esophageal cancer	3.39e-06	3.77e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—ABCB1—esophageal cancer	3.33e-06	3.71e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PTGS2—esophageal cancer	3.29e-06	3.67e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ALDH2—esophageal cancer	3.21e-06	3.57e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—HMOX1—esophageal cancer	3.19e-06	3.56e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	3.19e-06	3.55e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—HMOX1—esophageal cancer	3.16e-06	3.52e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CYP1B1—esophageal cancer	3.15e-06	3.51e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.1e-06	3.46e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.08e-06	3.43e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ABCB1—esophageal cancer	3.06e-06	3.41e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GSTT1—esophageal cancer	3.05e-06	3.4e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ABCB1—esophageal cancer	3.04e-06	3.38e-05	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PIK3CA—esophageal cancer	3.02e-06	3.36e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CYP2A6—esophageal cancer	3.02e-06	3.36e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—EP300—esophageal cancer	3.01e-06	3.35e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CYP19A1—esophageal cancer	2.96e-06	3.3e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ENO1—esophageal cancer	2.86e-06	3.19e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PTGS1—esophageal cancer	2.86e-06	3.19e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.82e-06	3.14e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PSME2—esophageal cancer	2.82e-06	3.14e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PSME1—esophageal cancer	2.82e-06	3.14e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—EP300—esophageal cancer	2.74e-06	3.05e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—CREBBP—esophageal cancer	2.72e-06	3.03e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—HMOX1—esophageal cancer	2.7e-06	3.01e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.65e-06	2.95e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ABCB1—esophageal cancer	2.6e-06	2.89e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.52e-06	2.81e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CREBBP—esophageal cancer	2.49e-06	2.78e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—NOS3—esophageal cancer	2.44e-06	2.71e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CYP1B1—esophageal cancer	2.43e-06	2.71e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.3e-06	2.56e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CYP19A1—esophageal cancer	2.29e-06	2.55e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—NOS3—esophageal cancer	2.23e-06	2.49e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PTGS2—esophageal cancer	2.23e-06	2.48e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CREBBP—esophageal cancer	2.23e-06	2.48e-05	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PIK3CA—esophageal cancer	2.23e-06	2.48e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CREBBP—esophageal cancer	2.17e-06	2.42e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—HMOX1—esophageal cancer	2.09e-06	2.32e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CREBBP—esophageal cancer	2.05e-06	2.28e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PTGS2—esophageal cancer	2.04e-06	2.27e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CREBBP—esophageal cancer	2.03e-06	2.26e-05	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PIK3CA—esophageal cancer	2.03e-06	2.26e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ABCB1—esophageal cancer	2e-06	2.23e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—NOS3—esophageal cancer	1.99e-06	2.22e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.96e-06	2.19e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—NOS3—esophageal cancer	1.95e-06	2.17e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—EP300—esophageal cancer	1.85e-06	2.06e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—NOS3—esophageal cancer	1.83e-06	2.04e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PTGS2—esophageal cancer	1.82e-06	2.03e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—NOS3—esophageal cancer	1.82e-06	2.02e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PTGS2—esophageal cancer	1.78e-06	1.98e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CREBBP—esophageal cancer	1.73e-06	1.93e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—EP300—esophageal cancer	1.7e-06	1.89e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PTGS2—esophageal cancer	1.68e-06	1.87e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PTGS2—esophageal cancer	1.66e-06	1.85e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—NOS3—esophageal cancer	1.55e-06	1.73e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—EP300—esophageal cancer	1.52e-06	1.69e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—EP300—esophageal cancer	1.48e-06	1.65e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PTGS2—esophageal cancer	1.42e-06	1.58e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—EP300—esophageal cancer	1.39e-06	1.55e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—EP300—esophageal cancer	1.38e-06	1.54e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PIK3CA—esophageal cancer	1.37e-06	1.53e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CREBBP—esophageal cancer	1.34e-06	1.49e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PIK3CA—esophageal cancer	1.26e-06	1.4e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—NOS3—esophageal cancer	1.2e-06	1.34e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—EP300—esophageal cancer	1.18e-06	1.32e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PIK3CA—esophageal cancer	1.12e-06	1.25e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.1e-06	1.22e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PIK3CA—esophageal cancer	1.09e-06	1.22e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PIK3CA—esophageal cancer	1.03e-06	1.15e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PIK3CA—esophageal cancer	1.02e-06	1.14e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—EP300—esophageal cancer	9.12e-07	1.02e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PIK3CA—esophageal cancer	8.74e-07	9.73e-06	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PIK3CA—esophageal cancer	6.75e-07	7.51e-06	CbGpPWpGaD
